Who is eligible for clinical trial NCT04665206?

Participants must meet the protocol's inclusion criteria for Solid Tumor, Adult. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT04665206 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-27

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (NCT04665206)

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Vivace Therapeutics, Inc

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (10 items).

Location: UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
ECOG: 0-1.
Adequate organ functions, including the liver, kidneys, and hematopoietic system.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Active brain metastases or primary CNS (central nervous system) tumors.
History of leptomeningeal metastases
Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Known HIV positive or active Hepatitis B or Hepatitis C
Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
Corrected QT (QTcF) interval \> 470 msec (using Fridericia's correction formula).
Additional active malignancy that may confound the assessment of the study endpoints
Women who are pregnant or breastfeeding
Prior treatment with TEAD inhibitor.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
University of Chicago Medical Center — Chicago, Illinois
Massachusetts General Hospital — Boston, Massachusetts
Dana-Farber Cancer Institute — Boston, Massachusetts
M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Memorial Sloan Kettering Cancer Center — New York, New York
MD Anderson Cancer Center — Houston, Texas
NEXT Oncology — San Antonio, Texas
Virginia Cancer Specialists, PC — Arlington, Virginia
Monash Health — Clayton, Victoria
Peter MacCullum Cancer Centre — Melbourne, Victoria
Linear Clinical Research — Nedlands, Western Australia

📞 Contact the Study Coordinator

Phone: (650) 627-7437

Email: hfritz@inclin.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor, Adult

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors — Los Angeles, California
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California

Explore by condition: All Solid Tumor, Adult clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗